The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 1 | — | 20.8x | Bottom tier | |
Growth | 29 | -123.0% | 6.1% | Bottom tier | |
Quality | 7 | -45.5% | 6.6% | Bottom tier | |
Safety | 34 | 0.2x | 0.7x | Bottom tier | |
Capital Return | 31 | 0.00% | 2.02% | Bottom tier | |
Momentum | 51 | -29.4% | 4.1% | Around median | |
Sentiment | 2 | 1 | 3 | Bottom tier |
ClearOne, Inc. is a company listed on NASDAQ under the ticker CLRO, with a market capitalization, according to the available data, of $11.3M. The provided materials do not offer a detailed operating description of ClearOne’s products, segments, or revenue model by business line, and there is no recent earnings call transcript explaining sales sources or margins for each activity. Therefore, the company can be analyzed here only through the revenue and earnings recorded in the available EDGAR filings, and through the recent merger news with Cortigent, a subsidiary of Vivani Medical.
The latest EDGAR data shown is classified as 2017 Q4 and shows revenue of $41.8M, gross profit of $24.0M, negative net income of $-14.2M, and EPS of -1.65. This equals a gross profit margin of about 57.4% and a net income margin of about -34.0%, meaning the company generated positive gross profit but recorded a large net loss in the displayed period. The provided financial statements do not show a segment mix or revenue breakdown between products or services, and the displayed 2017 FY figure matches the 2017 Q4 figure in revenue, gross profit, net income, and EPS, so additional operating details not present in the source should not be inferred.
Before the latest period, 2017 Q3 showed revenue of $10.6M, gross profit of $6.5M, and a net loss of $-9.3M, while 2017 Q2 recorded revenue of $10.3M and a net loss of -820000, and 2017 Q1 recorded revenue of $11.7M and a net loss of -468000. This sequence shows that losses were present in every quarterly period shown, with a clear deterioration in the net loss in Q3 and Q4 compared with Q1 and Q2. In contrast, gross profit remained positive in every displayed period, which is an important element but not sufficient on its own to confirm sustainable profitability at the net income level.
ClearOne’s valuation appears highly tied to corporate catalysts rather than current earnings, because the P/E ratio is not available in the data while a net loss of $-14.2M was recorded in the latest displayed financial period. The analyst consensus is buy, but the source does not provide a consensus price target, so it cannot be said from within this data that the stock is trading above or below the analysts’ target. Compared with the 52-week range of $2.71 to $12.25 and the market capitalization of $11.3M, the stock remains in a valuation framework that is highly sensitive to news and volatility.
Figures in the text are as of 2026-07-06; the live price is shown at the top of the page.
The most prominent catalyst in the data is the 2026-07-02 news that ClearOne is merging with Cortigent, a subsidiary of Vivani Medical, for a Nasdaq listing. This news was classified with an impact of 5/10 and a bullish direction, which is the highest impact among the news items provided over the last 30 days. On the same day, another news item mentioned a surge in small-cap stocks led by ClearOne amid a wave of merger deals and corporate actions, and it was classified with an impact of 4/10.
The latest displayed EDGAR period is 2017 Q4, and ClearOne recorded revenue of $41.8M and gross profit of $24.0M. In contrast, net income was $-14.2M and EPS was -1.65, reflecting a large net loss. The gross margin is about 57.4%, while the net income margin is about -34.0%. The data does not show a segment mix or revenue breakdown by products or services.
The data shows the P/E ratio as unavailable, and this is consistent with the presence of net losses in the displayed financial periods. In 2017 Q4, the company recorded a net loss of $-14.2M and EPS of -1.65, not positive earnings that can be used to calculate a traditional P/E ratio. Therefore, the stock’s valuation in this data depends more on merger news, analyst consensus, and the trading range, not on a current earnings multiple.
Automated analysis for informational purposes only — not investment advice.
The first clear risk is the net loss, as ClearOne recorded losses in every displayed quarterly period from 2017 Q1 to 2017 Q4. The loss increased from -468000 in 2017 Q1 to $-9.3M in 2017 Q3 and then $-14.2M in 2017 Q4. The second risk is the limited modern information, because the source does not include an earnings call transcript or financial statements more recent than the displayed data. The 52-week range between $2.71 and $12.25 also indicates high volatility.
There is no insider trading data in the provided dataset. This means insider purchases or insider sales cannot be used to confirm the market’s reading of the merger news with Cortigent, a subsidiary of Vivani Medical. The absence of data does not necessarily mean negative or positive behavior, but it limits the evidence available to an investor looking for signals from management or insiders.
The current data mentions the merger news dated 2026-07-02 but does not show the terms of the deal or its expected financial impact on ClearOne. Therefore, the important details remain any subsequent disclosures about the deal structure, the Nasdaq listing, and its impact on the financial statements. It is also important to see data more recent than the 2017 figures, because the latest displayed period included revenue of $41.8M and a net loss of $-14.2M. Any information about products or segments after the deal will also be important because the current source does not provide a segment mix.